Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'

22nd January 2020 Uncategorised 0

Amid new launches and fierce fights for share in key markets, several Johnson & Johnson meds scored wins against generic and biosimilar competition last year. But now that it’s 2020, that success is proving to be a double-edged sword.

More: Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'
Source: fierce